Marshall FF, Dietrick DD, Baumgartner WA et al (1988) Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol 139(6):1166–1172. https://doi.org/10.1016/s0022-5347(17)42848-5

Article  CAS  PubMed  Google Scholar 

Blute ML, Leibovich BC, Lohse CM et al (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94(1):33–41. https://doi.org/10.1111/j.1464-410X.2004.04897.x

Article  PubMed  Google Scholar 

Pouliot F, Shuch B, Larochelle JC et al (2010) Contemporary management of renal tumors with venous tumor thrombus. J Urol 184(3):833–841. https://doi.org/10.1016/j.juro.2010.04.071

Article  PubMed  Google Scholar 

Kalapara AA, Frydenberg M (2020) The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Transl Androl Urol 9(6):3123–3139. https://doi.org/10.21037/tau-19-327

Article  PubMed  PubMed Central  Google Scholar 

Horn T, Thalgott MK, Maurer T et al (2012) Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus. Anticancer Res 32(5):1729–1735

CAS  PubMed  Google Scholar 

Bigot P, Fardoun T, Bernhard JC et al (2014) Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol 32(1):109–114. https://doi.org/10.1007/s00345-013-1088-1

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300. https://doi.org/10.1056/NEJMoa2035716

Article  CAS  PubMed  Google Scholar 

Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841. https://doi.org/10.1056/NEJMoa2026982

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshida K, Hata K, Iizuka J et al (2022) Immune checkpoint inhibitor combination therapy for renal cell carcinomas with concomitant inferior vena cava thrombi. In vivo 36(2):1030–1034. https://doi.org/10.21873/invivo.12798

Article  PubMed  PubMed Central  Google Scholar 

Otsuka H, Masui K, Hosomi T et al (2022) Preoperative ipilimumab/nivolumab combination therapy reduced operation risk by downstaging the inferior vena cava tumor thrombus extending to the right atrium in a metastatic renal cell carcinoma: a case report. Urol Case Rep 40:101912. https://doi.org/10.1016/j.eucr.2021.101912

Article  PubMed  Google Scholar 

Tobe T, Terakawa T, Hara T et al (2023) The efficacy of presurgical therapy with Avelumab and Axitinib for renal cell carcinoma with inferior vena cava tumor thrombus. Clin Genitourin Cancer 21(5):613.e611-613.e616. https://doi.org/10.1016/j.clgc.2023.04.010

Article  Google Scholar 

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

Article  PubMed  PubMed Central  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

Article  CAS  PubMed  Google Scholar 

Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379(5):417–427. https://doi.org/10.1056/NEJMoa1803675

Article  PubMed  Google Scholar 

Wang H, Chen X, Wang K et al (2024) Risk factors for incident venous thromboembolism in patients with renal tumor and inferior vena cava tumor thrombus: a retrospective case-control study. Int J Surg 110(1):4–10. https://doi.org/10.1097/js9.0000000000000832

Article  PubMed  Google Scholar 

Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. https://doi.org/10.1056/NEJMoa1303989

Article  CAS  PubMed  Google Scholar 

Sternberg CN, Motzer RJ, Hutson TE et al (2019) COMPARZ post hoc analysis: characterizing pazopanib responders with advanced renal cell carcinoma. Clin Genitourin Cancer 17(6):425-435.e424. https://doi.org/10.1016/j.clgc.2019.01.015

Article  PubMed  PubMed Central  Google Scholar 

Shah DR, Dholakia S, Shah RR (2014) Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients. Drug Saf 37(3):135–149. https://doi.org/10.1007/s40264-014-0139-x

Article  CAS  PubMed  Google Scholar 

Lacy SA, Miles DR, Nguyen LT (2017) Clinical pharmacokinetics and pharmacodynamics of Cabozantinib. Clin Pharmacokinet 56(5):477–491. https://doi.org/10.1007/s40262-016-0461-9

Article  PubMed  Google Scholar 

Chen Y, Tortorici MA, Garrett M et al (2013) Clinical pharmacology of axitinib. Clin Pharmacokinet 52(9):713–725. https://doi.org/10.1007/s40262-013-0068-3

Article  CAS  PubMed  Google Scholar 

Boss DS, Glen H, Beijnen JH et al (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106(10):1598–1604. https://doi.org/10.1038/bjc.2012.154

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graafland NM, Szabados B, Tanabalan C et al (2022) Surgical safety of deferred cytoreductive nephrectomy following pretreatment with immune checkpoint inhibitor-based dual combination therapy. Eur Urol Oncol 5(3):373–374. https://doi.org/10.1016/j.euo.2021.11.004

Article  PubMed  Google Scholar 

Pignot G, Thiery-Vuillemin A, Albigès L et al (2022) Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma. Eur Urol Oncol 5(5):577–584. https://doi.org/10.1016/j.euo.2022.07.002

Article  PubMed  Google Scholar 

Ueki H, Terakawa T, Ueno Y et al (2022) Efficacy of preoperative cine magnetic resonance imaging in evaluation of adhesion of renal cancer thrombus to inferior vena cava wall. J Vasc Surg Venous Lymphat Disord 10(4):908–915. https://doi.org/10.1016/j.jvsv.2022.02.016

Article  PubMed  Google Scholar